Summary & Overview
HCPCS Level II Q4233: Surfactor or nudyn, per 0.5 cc
HCPCS Level II code Q4233 denotes a unit of surfactant product—“Surfactor or nudyn, per 0.5 cc”—used primarily in acute care settings for respiratory support. Nationally, accurate coding for surfactant products matters for hospital billing, neonatal care reimbursements, and pharmaceutical inventory tracking. This code identifies a small-dose surfactant unit commonly administered in hospital inpatient wards and neonatal intensive care units.
Key payers referenced in standard analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding intent, clinical context for surfactant administration, and what metrics are typically assessed when benchmarking utilization and reimbursement. The publication outlines payer coverage patterns, common claim considerations, and how this HCPCS Level II code fits into service lines that involve respiratory therapy and neonatal critical care. It highlights where data are typically required for claim adjudication and what information is usually included on service lines for surfactant administration.
This summary is intended for clinicians, coding professionals, and policy analysts seeking a clear, national-level snapshot of HCPCS Level II code Q4233 and its role in acute respiratory care billing.
Billing Code Overview
HCPCS Level II code Q4233 describes Surfactor or nudyn, per 0.5 cc. This product is a surfactant preparation intended for administration in small, measured volumes. The service type is pharmaceutical/supply administration involving the provision or use of a respiratory surfactant agent. The typical site of service is hospital inpatient or neonatal intensive care unit (NICU) settings where surfactant therapy is administered to patients with respiratory distress or related pulmonary conditions.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A neonate born at 28 weeks gestation develops respiratory distress within minutes of birth characterized by tachypnea, retractions, and oxygen requirement despite supplemental oxygen and continuous positive airway pressure (CPAP). A chest radiograph demonstrates low lung volumes and diffuse reticulogranular opacities consistent with neonatal respiratory distress syndrome (surfactant deficiency). The neonatology team elects to administer intratracheal surfactant therapy using Q4233 (Surfactor or nudyn, per 0.5 cc) via endotracheal tube after endotracheal intubation in the neonatal intensive care unit (NICU).
The clinical workflow includes pre-procedure stabilization and monitoring, endotracheal intubation by a neonatal provider, preparation of the surfactant dose based on weight and vial volume, aseptic instillation into the endotracheal tube, brief manual ventilation or positive-pressure ventilation to distribute surfactant, and post-procedure respiratory support and monitoring for changes in oxygenation, ventilation, heart rate, and potential complications (e.g., bradycardia, desaturation). Medication administration documentation includes product name, lot number, volume administered (recorded in 0.5 cc units), route (intratracheal), time, and the performing provider and assisting staff. Billing uses Q4233 units corresponding to the total 0.5 cc increments administered.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|